ArticleClinicoEconomics and outcomes research : CEOR2019

Erratum: Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum].

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.